مباشر
FierceBiotechInnovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADCPharmaVoiceHouse bill aims to crack down on China biotech dealsPharmaVoicePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?FierceBiotechMedline earns FDA warning letter ire for repeated toxic bacteria problemsFierceBiotechFrom business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’BrukerBruker showcases expanded microbiology diagnostics portfolio - Investing.comBrukerBruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報Endpoints NewsADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesEli LillyEli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical TechnologyEli LillyEli Lilly forms billion-dollar genetic kidney disease partnership with US biotech Ascidian Therapeutics - medwatch.comFierceBiotechAlnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneerSamsung BiologicsGlobal firms tighten hold on Korea’s biopharma supply chain - KED Global
FierceBiotech ٢٧ فبراير ٢٠٢٦

Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.